1. AHRO : Austin Health Research Online

Thomas John

View Statistics Email Alert RSS Feed
 Claim profile

Profile

Loading... 2 0 20 0 false
Credit Name
Thomas John
Full Name
John, Thomas
 
Variants
John, Tom
 
Department
 
Personal Site
https://www.onjcancercentre.org/profile/a-prof.-tom-john
 
ORCID
Loading... 3 0 20 0 false

Publications

Refined By:
Date Issued:  [2010 TO 2019]

Results 1-20 of 61 (Search time: 0.01 seconds).

Publication YearTitleAuthor(s)
1Dec-2019RET-rearranged non-small-cell lung cancer and therapeutic implications.Loh, Zoe ; Mitchell, Paul L R ; John, Thomas ; Arulananda, Surein
2Dec-2019Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer.Pavlakis, Nick; Cooper, Caroline; John, Thomas ; Kao, Steven; Klebe, Sonja; Lee, Chee Khoon; Leong, Trishe Y-M; Millward, Michael; O'Byrne, Ken; Russell, Prudence A; Solomon, Benjamin; Cooper, Wendy A; Fox, Stephen
318-Oct-2019Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.Felip, Enriqueta; de Braud, Filippo G; Maur, Michela; Loong, Herbert H; Shaw, Alice Tsang; Vansteenkiste, Johan F; John, Thomas ; Liu, Geoffrey; Lolkema, Martijn P; Selvaggi, Giovanni; Giannone, Vanessa; Cazorla, Pilar; Baum, Jason; Balbin, O Alejandro; Wang, Luojun Victor; Lau, Yvonne Y; Scott, Jeffrey W; Shao-Weng Tan, Daniel
49-Oct-2019Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.Brown, Helen; Vansteenkiste, Johan; Nakagawa, Kazuhiko; Cobo, Manuel; John, Thomas ; Barker, Craig; Kohlmann, Alexander; Todd, Alexander; Saggese, Matilde; Chmielecki, Juliann; Markovets, Aleksandra; Scott, Marietta; Ramalingam, Suresh S
5Sep-2019DDR Alterations as a Surrogate Marker for TMB in SCLC - Use it or Lose it?Arulananda, Surein; Mitchell, Paul L R ; John, Thomas 
6May-2019Standard dose osimertinib for erlotinib refractory T790M-negative EGFR-mutant non-small cell lung cancer with leptomeningeal disease.Arulananda, Surein; Do, Hongdo; Rivalland, Gareth; Loh, Zoe ; Musafer, Ashan; Lau, Eddie ; Mitchell, Paul; Dobrovic, Alexander ; John, Thomas 
724-Apr-2019BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.Lee, Erinna F; Harris, Tiffany J ; Tran, Sharon; Evangelista, Marco; Arulananda, Surein; John, Thomas ; Ramnac, Celeste; Hobbs, Chloe; Zhu, Haoran; Gunasingh, Gency; Segal, David; Behren, Andreas; Cebon, Jonathan S ; Dobrovic, Alexander ; Mariadason, John M ; Strasser, Andreas; Rohrbeck, Leona; Haass, Nikolas K; Herold, Marco J; Fairlie, W Douglas
85-Apr-2019Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.Li, Na; McInerny, Simone; Zethoven, Magnus; Cheasley, Dane; Lim, Belle W X; Rowley, Simone M; Devereux, Lisa; Grewal, Norah; Ahmadloo, Somayeh; Byrne, David; Lee, Jue Er Amanda; Li, Jason; Fox, Stephen B; John, Thomas ; Antill, Yoland; Gorringe, Kylie L; James, Paul A; Campbell, Ian G
9Apr-2019Osimertinib as first-line (1L) treatment for epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC): Final efficacy and safety results from two phase I expansion cohorts.Yang, J C-H; Ramalingam, S S; Lee, C K; Kurata, T; Kim, D-W; John, Thomas ; Nogami, N; Ohe, Y; Rukazenkov, Y; Murphy, M; Jänne, P A
10Apr-2019Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort.Rivalland, Gareth; Mitchell, Paul L R ; Murone, Carmel ; Asadi, Khashayer; Morey, Adrienne L; Starmans, Maud; Boutros, Paul C; Walkiewicz, Marzena; Solomon, Benjamin; Wright, Gavin; Knight, Simon; John, Thomas 
11Apr-2019Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2.Barlesi, F; Drilon, A; De Braud, F; Cho, B C; Ahn, M J; Siena, S; Krebs, M G; Lin, C C; John, Thomas ; Tan, D S W; Seto, T; Dziadziuszko, R; Arkenau, H-T; Rolfo, C; Wolf, J; Ye, C; Riehl, T; Eng, S; Doebele, R C
12Apr-2019Entrectinib in NTRK fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of patients (pts) enrolled in STARTRK-2, STARTRK-1 and ALKA-372-001.Paz-Ares, L; Doebele, R C; Farago, A F; Liu, S V; Chawla, S P; Tosi, D; Blakely, C M; Krauss, J C; Sigal, D; Bazhenova, L; John, Thomas ; Besse, B; Wolf, J; Seto, T; Chow-Maneval, E; Ye, C; Simmons, B; Demetri, G D
1327-Mar-2019Epidermal growth factor receptor (EGFR)-targeted therapies in Mesothelioma.Chia, Puey Ling ; Scott, Andrew M ; John, Thomas 
142019The Impact of Universal Immunohistochemistry on Lynch Syndrome Diagnosis in an Australian Colorectal Cancer Cohort.Loh, Zoe ; Williams, David S ; Salmon, Lucinda ; Dow, Eryn; John, Thomas 
152019Effect of Reasons for Screen Failure on Subsequent Treatment Outcomes in Cancer Patients Assessed for Clinical Trials.Tiu, Crescens; Loh, Zoe ; Gan, Chun Loo; Gan, Hui K ; John, Thomas ; Hawkes, Eliza A 
16Dec-2018EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.John, Thomas ; Akamatsu, Hiroaki; Delmonte, Angelo; Su, Wu-Chou; Lee, Jong Seok; Chang, Gee-Chen; Huang, Xiangning; Jenkins, Suzanne; Wu, Yi-Long
17Sep-2018LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.Lee, Rachael Chang; Thapa, Bibhusal ; John, Thomas 
18Jun-2018Can molecularly targeted therapy cure patients with resected EGFR mutant NSCLC?Klevansky, Myron ; John, Thomas 
191-Apr-2018Personalized Chemosensitivity Assays for Mesothelioma: Are They Worth the Effort?John, Thomas ; Chia, Puey Ling 
20Feb-2018In Reply to Leone.Do, Hongdo; Arulananda, Surein; John, Thomas ; Dobrovic, Alexander